The purpose of this symposium is to evaluate the effects of current treatment and discuss new therapies for chronic lymphocytic leukemia (CLL).
Program Goals
At the conclusion of the course, participants should be able to:
- Evaluate the biologic underpinnings that allow the new kinase inhibitors, Ibrutinib and Idelalisib, to have such profound effects on CLL cells and on patient quality of life.
- Develop strategies to incorporate new non-chemotherapeutic therapies into practice as they become available and determine how these might augment and/or replace existing medications.
- Analyze key unanswered questions about the growth, survival, and elimination of CLL clones in patients.
To register, please choose one of the following:
CME Registration ($50)
Standard Registration ($20)
The post Centricity Series: Chronic Lymphocytic Leukemia appeared first on The Feinstein Institute for Medical Research.